Overview

Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesise that phosphodiesterase 5A inhibitors will improve exercise capacity in those with Chronic Obstructive Pulmonary Disease and secondary pulmonary hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
University of Dundee
Collaborators:
Chief Scientist Office of the Scottish Government
NHS Fife
NHS Tayside
Treatments:
Tadalafil